Study of QY-1-T for advanced HBV-related liver cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new treatment called QY-1-T for people with advanced liver cancer related to hepatitis B. It is for patients who have already tried other standard treatments and have a certain genetic marker (HLA-A*11:01).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have advanced liver cancer (hepatocellular carcinoma) that cannot be treated with surgery or local therapy, and you have already tried at least two standard treatments (like targeted therapy, immunotherapy, or chemotherapy) that didn't work or caused side effects.
- Your blood test must show a specific genetic marker called HLA-A*11:01.
- You must have hepatitis B (HBV) infection now or in the past, and your liver function is still fairly good (Child-Pugh score less than 7, meaning no or mild cirrhosis).
- You cannot have recent (within 1 month) immunotherapy with checkpoint blockers, and you must not have other serious medical conditions like uncontrolled high blood pressure or recent bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This trial tests a combination of an immunotherapy drug (QL1706) and a liver-directed procedure (TACE) before and after surgery for people with liver cancer that is larger or more advanced than the usual transplant criteria. The goal is to see if this approach can help shrink the tumor and improve outcomes.
This Phase 1 study tests a lab-made immune cell treatment that targets hepatitis B (HBV)–related liver cancer. It may help by directing the body’s immune system to attack the cancer, while carefully checking safety.
This trial tests a new drug called QL1706 for people with advanced liver cancer that has worsened after a previous immunotherapy treatment. The goal is to see if it can help slow down the cancer.
This trial tests a new way to find and treat liver cancer that cannot be removed by surgery. First, a special dye (RYZ811) is used to see if your cancer cells have a marker called GPC3. If they do, you may receive a targeted radiation treatment (RYZ801) that seeks out those cells. This trial is for people whose liver cancer has grown despite receiving at least one prior therapy.
This trial tests a combination of a special type of radiation (SBRT) and an immunotherapy drug (QL1706) as a second option for people with advanced liver cancer that hasn't been controlled by initial treatment.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.